Business | A new opening?

The mind-bending new rules for doing business in China

Xi Jinping is sending mixed messages to Western bosses and investors

Illustration of a traditional Chinese double door, with the top half swung open and the bottom half closed. The doors feature ornate carvings or decorations typical of Chinese architecture.
Illustration: Rose Wong
|Beijing

FOR YEARS foreign companies were desperate to get into China, and faced formidable bureaucratic obstacles in their way. Now many are getting out. Over the past 12 months several foreign law firms have closed some or all of their Chinese offices. Orrick, Herrington & Sutcliffe, an American one, said on March 22nd it would shut the Shanghai office it opened 20 years ago. Another, Akin Gump Strauss Hauer & Feld, plans to exit China altogether this year. Some global investment banks are pruning their Chinese staff. So are a few large accountancies and due-diligence groups. In 2023 foreign direct investment in China fell to its lowest level in 30 years.

One reason for foreigners’ change of heart is the sorry state of the Chinese economy. Of the 18 largest multinational companies that report their earnings from China, 13 saw annual revenues there fall in 2023. Qualcomm and Samsung, two technology giants, recorded sales drops of more than 20%. Apple sold nearly a quarter fewer iPhones in the first six weeks of 2024 than it did in the same period the year before. In February Tesla shifted 19% fewer electric cars. Weak Chinese sales are the main reason why Kering, the French owner of Gucci, expected to flog a fifth less of its bling in Asia in the first quarter.

Explore more

This article appeared in the Business section of the print edition under the headline "A new opening?"

China’s risky reboot

From the April 6th 2024 edition

Discover stories from this section and more in the list of contents

Explore the edition

More from Business

Chinese EV-makers are leaving Western rivals in the dust

They have shone at Beijing’s car jamboree

Can biotech startups upstage Eli Lilly and Novo Nordisk?

Smaller drugmakers are enjoying a revival


How to handle populists: a CEO’s survival guide

Western businesses are learning to live with volatile electoral politics around the world